FINWIRES · TerminalLIVE
FINWIRES

Metcash Expects Year-Over-Year Increase in Fiscal Year 2026 Revenue

By

-- Metcash (ASX:MTS) expects fiscal year 2026 revenue of AU$19.6 billion, up 0.7% from the previous year, according to a Monday filing with the Australian bourse.

The company also expects fiscal year underlying profit after tax in the range of AU$268 million to AU$270 million.

Metcash said ongoing cost initiatives are expected to yield at least around AU$25 million of annualized savings in fiscal year 2027.

Additionally, the company has increased inventory levels as a precaution, even though it has not yet experienced any supply shortages due to the Middle East conflict.

Related Articles

Asia

Bioxyne Unit Expands Supply Deal With Pharmaceutical Distributor; Shares Up 4%

Bioxyne's (ASX:BXN) Breathe Life Sciences subsidiary executed an expanded supply agreement with pharmaceutical distributor Remidose LATAM to include three Dr Watson cannabis flower stock-keeping unit (SKUs) to Costa Rica, according to a Monday filing with the Australian bourse.Initial shipment is scheduled before June 30, with an invoice value exceeding AU$500,000, the filing said.Shares rose 4% in morning trade on Monday.

$ASX:BXN
Asia

CSL Cuts Fiscal 2026 Outlook, Flags $5 Billion of Additional Impairments; Shares Hit Nine-Year Low

CSL (ASX:CSL) lowered its guidance for fiscal 2026 and expects to recognize about $5 billion of additional non-cash, pre-tax impairments across fiscal 2026 and 2027 beyond those the company disclosed earlier this year, according to a Monday filing with the Australian bourse.The biotechnology company now expects fiscal 2026 revenue of around $15.2 billion and net profit after tax adjusted to exclude amortization (NPATA) of around $3.1 billion, both on a constant-currency basis.In February, it guided for 2% to 3% growth in revenue and 4% to 7% growth in NPATA.The $5 billion of additional impairments include CSL Vifor intangible assets, including the product portfolio, as well as under-utilized property, plant and equipment, the company said.CSL flagged a roughly $300 million fiscal 2026 revenue impact from its "normalization of channel inventory" for US immunoglobulin, a roughly $200 million hit from albumin in China, and an impact of about $150 million from other factors including the Middle East conflict."Our growth initiatives are working, but the financial benefits will take longer than previously anticipated to materialize," said interim CEO Gordon Naylor.The company's shares tumbled 17% in recent Monday trade and earlier hit their lowest since December 2016.

$ASX:CSL
Asia

QBE Insurance Group to Redeem Over $524 Million Subordinated Notes

QBE Insurance Group (ASX:QBE) said it will fully redeem its $524.1 million 5.875% subordinated notes due 2046 on June 17, paying investors the principal amount plus accrued interest, according to a Monday filing with the Australian bourse.The redemption has been approved by the Australian Prudential Regulation Authority (APRA), per the filing.The company clarified that this does not imply any intention to redeem other regulatory capital instruments, which would still require separate APRA approval, the filing added.

$ASX:QBE